Clinical Trial I

A service of the U.S. National Institutes of Health

Search for studies:

Advanced Search Help Studies by Topic Glossary

Phase 1/2 Lyme Vaccine Study

This study has been completed.

Sponsor:

Baxter Healthcare Corporation

Collaborator:

Baxter Innovations GmbH

Information provided by (Responsible Party):

Baxter Healthcare Corporation

ClinicalTrials.gov Identifier:

NCT01504347

First received: December 22, 2011

Last updated: March 25, 2014

Last verified: March 2014

History of Changes

Full Text View

Tabular View

No Study Results Posted

Disclaimer

How to Read a Study Record

Purpose

Section 1:

The purpose of the study is to obtain safety and immunogenicity data of different dose levels of a multivalent recombinant OspA Lyme Borreliosis (mv rOspA LB) Vaccine with and without adjuvant in seronegative healthy adults aged 18 to 70 years. The outcome shall provide the basis for dose/formulation selection for Section 2 of the study.

Section 2:

An additional purpose of the study is to evaluate the safety and immunogenicity of the optimal dose(s)/formulation of the mv rOspA LB Vaccine in a larger population of seronegative and seropositive healthy subjects aged 18 to 70 years.

Condition

Prophylaxis of Lyme Borreliosis

Intervention

Biological: Multivalent recombinant OspA Lyme Borreliosis Vaccine

Phase

Phase 1

Phase 2

Further study details as provided by Baxter Healthcare Corporation:

Primary Outcome Measures:

Antibody response to the vaccine [ Time Frame: 28 days after the third vaccination (= Day 85) ] [ Designated as safety issue: No ]
Frequency and severity of injection site and systemic reactions [ Time Frame: Within 7 days after each vaccination (i.e. Days 8, 36 and 64) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Antibody response [ Time Frame: At baseline, 28 days after each vaccination (i.e. Days 29, 57 and 85), 180 and 270 days after the first vaccination (Day 181, Day 271) and 180 days after the booster vaccination (Day 361 or Day 451 - 546) ] [ Designated as safety issue: No ]
Fold increase in antibody titer compared to baseline [ Time Frame: 28 days after each vaccination, 180 and 270 days after the first vaccination and 180 days after the booster vaccination ] [ Designated as safety issue: No ]
Seroconversion rate (at least 4-fold increase of each rOspA type-specific Immunoglobulin G (IgG) titer) as compared to baseline [ Time Frame: 28 days after each vaccination, 180 and 270 days after the first vaccination and 180 days after the booster vaccination ] [ Designated as safety issue: No ]
Frequency and severity of adverse events [ Time Frame: 28 days after each vaccination and during entire study period ] [ Designated as safety issue: Yes ]

Eligibility

Criteria

Main Inclusion Criteria:

Subject is 18 to 70 years old at the time of screening
Subject has an understanding of the study, agrees to its provisions, and gives written informed consent prior to study entry
Subject is generally healthy, as determined by the investigator's clinical judgment through collection of medical history and the performance of a physical examination
If female of childbearing potential, presents with a negative urine pregnancy test, and agrees to employ adequate birth control measures for the duration of the study

Additional inclusion criterion for seropositive subjects in Section 2 only:

- Subject is seropositive for Borrelia burgdorferi sensu lato (s.l.) antibodies at study entry

Main Exclusion Criteria:

Subject has a physician-diagnosed chronic illness related to Lyme borreliosis (LB) or active LB
Subject has been treated for LB with antibiotics within 3 months of study entry
Subject had a tick bite within 3 weeks prior to screening or first vaccination
Subject has a history or active infection with Babesia microti (babesiosis) or Anaplasma phagocytophilum (ehrlichiosis)
Subject currently has or has a history of significant cardiovascular, respiratory (including asthma), metabolic, neurological, hepatic, rheumatic, autoimmune, hematological, gastrointestinal or renal disorder
Subject has clinically significant abnormal laboratory values at screening
Subject currently has or has a history of immunodeficiency
Subject tests positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)
Subject has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that could be expected to influence immune response.
Subject has a history of anaphylaxis or severe allergic reactions
Subject has received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study
Subject is pregnant or lactating at the time of study enrollment

Additional exclusion criterion for subjects in Section 1 and seronegative subjects in Section 2:

- Subject is seropositive for Borrelia burgdorferi sensu lato (s.l.) antibodies at study entry

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01504347

Locations